Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
UCSF daptomycin - adult dosing guidance
Product / population
Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Renal method
Institutional CrCl headings; source-specific weight selection and CVVHD flow caveats
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-10
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Do not merge label and higher-dose institutional dialysis protocols
The label includes CrCl exactly 30 in its >=30 band. UCSF prints >30 and <30, omitting exactly 30, and uses higher doses and different HD scheduling.
What to reconcile: Keep source-specific dose, interval, indication, weight basis and modality together. The official threshold is explicit; seek institutional clarification rather than silently changing its headings.
UCSF Infectious Diseases Management Program · Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Renal method: Institutional CrCl headings; source-specific weight selection and CVVHD flow caveats Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-10
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Before using this finding
Higher-dose institutional regimens and the missing exactly-30 heading require source-specific review, not dose/interval mixing.
Dialysis evidence: A regimen is reported in selected content
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
UCSF prints CrCl >30 and <30 headings with 8-10 mg/kg IV every 24 and 48 hours, respectively; exactly 30 is absent from those headings. Its intermittent-HD schedule is 8-10 mg/kg once now and after HD, with every-48-hour dosing as an alternative when the HD schedule is unstable. CVVHD uses 6-8 mg/kg every 24 hours; flow above 2.5 L/hour may require more with ID/ASP input. Other continuous modalities, including CVVH, were not evaluated. UCSF uses total weight unless above 120% of ideal weight, then adjusted weight. Therapy is restricted and is not for pneumonia.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.